ETFs
Z
ZBIO
Zenas BioPharma Inc.
29.04
+2.33+8.70%Opening12:57 10/20 EDT
OPEN/PREV CLOSE26.38/26.71
TODAY RANGE26.38-29.30
VOL162.05K
MARKET CAP1.89B
52 WEEK RANGE13.50-44.60
AVG VOL (3M)704.42K
% TURNOVER0.25%
TURNOVER--
P/E (TTM)-3.2360
% RANGE10.91%
EPS(TTM)-8.9724
P/E(FORWARD)-5.1532
P/B7.44
BVPS3.902
DIVIDEND--
P/S158.23
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.45B
SHARES OUTSTANDING65.18M
NEXT EARNINGS11/10-11/16
FREE FLOAT49.91M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
Learn Why The Bull Case For Zenas BioPharma Stock Could Change Following Phase 3 Data
Simply Wall St·4d ago
Zenas BioPharma (ZBIO) INDIGO Data Puts Its Bull Case Back In Focus
TipRanks·10/13 13:55
Wedbush Remains a Buy on Zenas BioPharma, Inc. (ZBIO)
Dow Jones·10/13 10:44
Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.
TipRanks·10/13 10:34
Zenas BioPharma Highlights New Phase 3 Obexelimab Data
TipRanks·10/12 11:15
Zenas BioPharma presents new obexelimab data
Simply Wall St·10/09 12:40
Zenas BioPharma Stock Is Down 6.9% Has The Bull Case Changed After Trial Updates
Simply Wall St·10/08 10:25
Zenas BioPharma (ZBIO) Highlights New Clinical Data, Is It Still 52% Below Fair Value?
Seeking Alpha·10/05 09:09
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Dow Jones·09/30 20:45
Zenas BioPharma Price Target Raised to $48.00/Share From $41.00 by Citigroup
Dow Jones·09/30 20:45
Zenas BioPharma Is Maintained at Buy by Citigroup
Same Industry
Name/Symbol
Change%
Price